CAR T‐cells merge into the fast lane of cancer care. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Frey, Noelle V.; Porter, David L.
• Other Names: Tefferi Ayalew guestEditor.
• Is Part Of: American journal of hematology. Volume 91:Issue 1(2016:Jan.)
• Page Start: 146
• Page End: 150
• Publication Date: 2016-01
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24238
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract : Chimeric antigen receptors (CARs) can be introduced into T‐cells redirecting them to target specific tumor antigens. CAR‐modified T cells targeting CD19 have shown remarkable activity against CD19+ malignancies including B cell acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non‐Hodgkin lymphomas (NHL). Complete remission rates as high as 90% have been observed for patients with relapsed and refractory ALL and greater than 50% response rates have been seen in heavily pre‐treated CLL and NHL. Excitingly, some remissions have been durable without any additional therapy, a finding which correlates with in‐vivo T‐cell persistence and B‐cell aplasia. The major treatment related toxicities include B‐cell aplasia, neurologic toxicities, and a potentially severe cytokine release syndrome. This review summarizes outcomes for patients treated with CD19‐CAR T‐cells while exploring the field's challenges and future directions. Am. J. Hematol. 91:146–150, 2016. © 2015 Wiley Periodicals, Inc.